dexmedetomidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
835 113775-47-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexmedetomidine
  • (S)-Medetomidine
  • dexmedetomidine hydrochloride
  • dexdor
  • dexmedetomidine HCl
  • MPV1440
  • precedex
A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.
  • Molecular weight: 200.29
  • Formula: C13H16N2
  • CLOGP: 3.10
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 28.68
  • ALOGS: -3.06
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.09 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 20 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Dec. 17, 1999 FDA HOSPIRA
Jan. 29, 2001 PMDA Abbott Japan, Maruishi Pharmaceutical
Sept. 15, 2011 EMA Orion Corporation

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 236.92 30.29 108 3953 73119 63411842
Product administered to patient of inappropriate age 119.31 30.29 30 4031 3238 63481723
Hypotension 87.69 30.29 97 3964 272507 63212454
Delirium 82.28 30.29 47 4014 50494 63434467
Agitation 80.07 30.29 49 4012 59708 63425253
Upper airway obstruction 78.07 30.29 16 4045 687 63484274
Floppy iris syndrome 76.08 30.29 12 4049 110 63484851
Respiratory depression 73.42 30.29 29 4032 13686 63471275
Glossoptosis 73.15 30.29 11 4050 71 63484890
Cardiac arrest 71.59 30.29 54 4007 92491 63392470
Withdrawal syndrome 69.21 30.29 31 4030 19966 63464995
Respiratory acidosis 69.05 30.29 23 4038 6692 63478269
Sinus arrest 61.83 30.29 16 4045 1933 63483028
Respiratory failure 56.61 30.29 49 4012 101809 63383152
Off label use 56.36 30.29 129 3932 674333 62810628
Generalised tonic-clonic seizure 55.44 30.29 30 4031 28986 63455975
Laryngeal stenosis 55.20 30.29 13 4048 1065 63483896
Tachyphylaxis 53.42 30.29 10 4051 266 63484695
Hepatic function abnormal 51.11 30.29 31 4030 37111 63447850
Stress cardiomyopathy 50.63 30.29 20 4041 9430 63475531
Drug reaction with eosinophilia and systemic symptoms 48.51 30.29 29 4032 33807 63451154
Local anaesthetic systemic toxicity 46.86 30.29 11 4050 888 63484073
Acute respiratory distress syndrome 46.82 30.29 25 4036 23509 63461452
Product closure removal difficult 44.43 30.29 6 4055 15 63484946
Hyperthermia 44.28 30.29 18 4043 9138 63475823
Ventricular dysfunction 42.77 30.29 13 4048 2815 63482146
Phaeochromocytoma crisis 41.65 30.29 8 4053 245 63484716
Myoclonus 40.68 30.29 20 4041 15848 63469113
Abdominal compartment syndrome 40.27 30.29 9 4052 584 63484377
Aplastic anaemia 40.16 30.29 17 4044 9552 63475409
Drug interaction 39.48 30.29 60 4001 229071 63255890
Unwanted awareness during anaesthesia 39.34 30.29 8 4053 330 63484631
Human herpesvirus 6 infection reactivation 38.53 30.29 8 4053 366 63484595
Laryngospasm 37.73 30.29 12 4049 3016 63481945
Posterior reversible encephalopathy syndrome 36.12 30.29 19 4042 17326 63467635
Device pacing issue 35.26 30.29 6 4055 91 63484870
Tachycardia 34.34 30.29 40 4021 118116 63366845
Hypernatraemia 33.54 30.29 14 4047 7595 63477366
Atrioventricular block second degree 30.88 30.29 11 4050 3903 63481058
Arteriospasm coronary 30.73 30.29 11 4050 3957 63481004
Postoperative ileus 30.62 30.29 7 4054 503 63484458
Accident at work 30.43 30.29 7 4054 517 63484444

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 371.60 24.32 207 6148 75211 34875365
Diabetes insipidus 267.56 24.32 69 6286 2859 34947717
Cardiac arrest 208.88 24.32 158 6197 96001 34854575
Hyperthermia 148.62 24.32 60 6295 10517 34940059
Intestinal pseudo-obstruction 144.05 24.32 38 6317 1718 34948858
Product administered to patient of inappropriate age 133.04 24.32 41 6314 3250 34947326
Arteriospasm coronary 115.32 24.32 37 6318 3345 34947231
Hyperthermia malignant 109.04 24.32 32 6323 2145 34948431
Drug withdrawal syndrome 101.42 24.32 56 6299 19778 34930798
Delirium 98.99 24.32 74 6281 43917 34906659
Hypotension 87.09 24.32 149 6206 221500 34729076
Seizure like phenomena 74.62 24.32 19 6336 745 34949831
Respiratory failure 71.32 24.32 93 6262 108479 34842097
Postoperative ileus 71.08 24.32 18 6337 690 34949886
Off label use 68.35 24.32 198 6157 419326 34531250
Serotonin syndrome 62.20 24.32 41 6314 19892 34930684
Acute motor axonal neuropathy 57.43 24.32 10 6345 55 34950521
Tachycardia 51.59 24.32 70 6285 84702 34865874
Burkholderia test positive 51.06 24.32 15 6340 1008 34949568
Sedation complication 50.72 24.32 17 6338 1760 34948816
Withdrawal syndrome 49.84 24.32 30 6325 12425 34938151
Electrocardiogram QT prolonged 47.17 24.32 47 6308 40905 34909671
Polyuria 45.98 24.32 25 6330 8549 34942027
Myoclonus 45.23 24.32 30 6325 14695 34935881
Epidermolysis bullosa 44.94 24.32 9 6346 115 34950461
Tachypnoea 43.75 24.32 32 6323 18320 34932256
Upper airway obstruction 43.31 24.32 12 6343 653 34949923
Drug ineffective for unapproved indication 42.68 24.32 35 6320 23680 34926896
Fatigue 40.54 24.32 9 6346 370644 34579932
Agitation 40.49 24.32 51 6304 57348 34893228
Malignant catatonia 38.79 24.32 9 6346 237 34950339
Torsade de pointes 38.60 24.32 21 6334 7188 34943388
Hyperaesthesia 37.99 24.32 18 6337 4612 34945964
Product use issue 36.61 24.32 51 6304 63165 34887411
Laryngomalacia 36.11 24.32 9 6346 323 34950253
Drug interaction 34.00 24.32 104 6251 225842 34724734
Product use in unapproved indication 33.45 24.32 69 6286 117430 34833146
Hypernatraemia 32.81 24.32 20 6335 8470 34942106
Floppy iris syndrome 31.53 24.32 8 6347 309 34950267
Multiple organ dysfunction syndrome 30.57 24.32 52 6303 76514 34874062
Urinary bladder rupture 29.19 24.32 6 6349 88 34950488
Cardiac arrest neonatal 28.79 24.32 5 6350 27 34950549
Sinus arrest 28.36 24.32 11 6344 1729 34948847
Haemodynamic instability 28.27 24.32 19 6336 9504 34941072
Neuroleptic malignant syndrome 27.20 24.32 24 6331 17910 34932666
Respiratory depression 27.19 24.32 23 6332 16222 34934354
Abdominal compartment syndrome 26.73 24.32 9 6346 944 34949632
Asthenia 26.67 24.32 6 6349 245245 34705331
Glossoptosis 26.55 24.32 6 6349 140 34950436
Drug withdrawal syndrome neonatal 26.46 24.32 13 6342 3606 34946970
Macule 26.19 24.32 10 6345 1507 34949069
Hypoxia 25.48 24.32 40 6315 55055 34895521
Transcranial electrical motor evoked potential monitoring abnormal 24.91 24.32 4 6351 12 34950564
Hypercapnia 24.47 24.32 13 6342 4242 34946334

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 472.77 25.06 260 9594 135297 79599237
Diabetes insipidus 272.89 25.06 73 9781 5164 79729370
Cardiac arrest 264.39 25.06 197 9657 171899 79562635
Product administered to patient of inappropriate age 204.65 25.06 59 9795 5494 79729040
Hyperthermia 187.68 25.06 74 9780 17963 79716571
Intestinal pseudo-obstruction 143.64 25.06 38 9816 2571 79731963
Delirium 138.92 25.06 101 9753 84526 79650008
Hypotension 137.56 25.06 216 9638 440101 79294433
Drug withdrawal syndrome 121.63 25.06 67 9787 34651 79699883
Arteriospasm coronary 112.06 25.06 39 9815 6677 79727857
Respiratory failure 111.32 25.06 124 9730 180787 79553747
Hyperthermia malignant 107.49 25.06 31 9823 2886 79731648
Respiratory depression 107.02 25.06 57 9797 27573 79706961
Postoperative ileus 106.33 25.06 25 9829 1040 79733494
Upper airway obstruction 104.02 25.06 26 9828 1402 79733132
Agitation 103.59 25.06 91 9763 99624 79634910
Withdrawal syndrome 102.89 25.06 55 9799 26799 79707735
Serotonin syndrome 88.40 25.06 60 9794 44967 79689567
Myoclonus 85 25.06 49 9805 27611 79706923
Off label use 84.33 25.06 274 9580 906941 78827593
Glossoptosis 79.01 25.06 15 9839 216 79734318
Polyuria 78.67 25.06 38 9816 14976 79719558
Tachypnoea 73.31 25.06 47 9807 32016 79702518
Tachycardia 72.32 25.06 99 9755 177669 79556865
Electrocardiogram QT prolonged 71.67 25.06 71 9783 90315 79644219
Generalised tonic-clonic seizure 71.06 25.06 52 9802 43858 79690676
Drug interaction 70.48 25.06 157 9697 415026 79319508
Drug ineffective for unapproved indication 70.35 25.06 55 9799 51183 79683351
Hypernatraemia 65.09 25.06 33 9821 14418 79720116
Seizure like phenomena 65.06 25.06 19 9835 1848 79732686
Sinus arrest 64.16 25.06 22 9832 3600 79730934
Abdominal compartment syndrome 63.45 25.06 18 9836 1579 79732955
Stress cardiomyopathy 57.70 25.06 28 9826 11138 79723396
Respiratory acidosis 57.62 25.06 28 9826 11172 79723362
Fatigue 56.96 25.06 22 9832 929705 78804829
Acute motor axonal neuropathy 55.58 25.06 10 9844 105 79734429
Arthralgia 55.40 25.06 4 9850 571799 79162735
Multiple organ dysfunction syndrome 51.96 25.06 69 9785 120177 79614357
Delayed recovery from anaesthesia 49.48 25.06 15 9839 1658 79732876
Hypoxia 48.90 25.06 62 9792 103181 79631353
Sedation complication 48.77 25.06 28 9826 15641 79718893
Torsade de pointes 48.37 25.06 30 9824 19282 79715252
Drug reaction with eosinophilia and systemic symptoms 48.21 25.06 49 9805 64195 79670339
Laryngeal stenosis 46.57 25.06 13 9841 1075 79733459
Atrioventricular block second degree 45.99 25.06 21 9833 7291 79727243
Product use in unapproved indication 45.01 25.06 97 9757 250262 79484272
Malaise 43.22 25.06 5 9849 489864 79244670
Ventricular tachycardia 42.95 25.06 38 9816 41897 79692637
Epidermolysis bullosa 42.93 25.06 9 9845 219 79734315
Nausea 42.26 25.06 34 9820 957162 78777372
Laryngospasm 40.15 25.06 16 9838 3981 79730553
Paradoxical drug reaction 40.11 25.06 19 9835 7166 79727368
Product closure removal difficult 40.00 25.06 5 9849 0 79734534
Headache 39.09 25.06 16 9838 653756 79080778
Haemodynamic instability 38.53 25.06 25 9829 17357 79717177
Local anaesthetic systemic toxicity 37.94 25.06 11 9843 1043 79733491
Ventricular fibrillation 36.89 25.06 31 9823 31895 79702639
Blood pressure decreased 36.83 25.06 53 9801 99413 79635121
Diarrhoea 36.73 25.06 33 9821 880456 78854078
Neuroleptic malignant syndrome 36.55 25.06 29 9825 27530 79707004
Malignant catatonia 36.55 25.06 9 9845 456 79734078
Hepatic function abnormal 36.36 25.06 45 9809 73062 79661472
Acute respiratory distress syndrome 35.61 25.06 35 9819 44032 79690502
Dizziness 34.65 25.06 11 9843 526430 79208104
Burkholderia test positive 34.50 25.06 9 9845 576 79733958
Phaeochromocytoma crisis 34.11 25.06 8 9846 329 79734205
Shock 34.10 25.06 34 9820 43514 79691020
Pain in extremity 34.01 25.06 3 9851 364535 79369999
Hyperpyrexia 33.67 25.06 16 9838 6076 79728458
Asthenia 33.13 25.06 11 9843 511678 79222856
Weight decreased 32.93 25.06 3 9851 355195 79379339
Transcranial electrical motor evoked potential monitoring abnormal 32.82 25.06 5 9849 16 79734518
Airway complication of anaesthesia 32.36 25.06 8 9846 412 79734122
Atrioventricular block complete 32.26 25.06 22 9832 16588 79717946
Drug ineffective 31.87 25.06 235 9619 1080678 78653856
Oxygen saturation decreased 31.64 25.06 57 9797 128990 79605544
Aplastic anaemia 30.76 25.06 22 9832 17883 79716651
Hyperaesthesia 30.64 25.06 19 9835 12203 79722331
Hypercapnia 30.60 25.06 17 9837 8918 79725616
Human herpesvirus 6 infection reactivation 29.86 25.06 8 9846 567 79733967
Anaphylactic shock 29.85 25.06 29 9825 35967 79698567
Septic shock 29.80 25.06 54 9800 122747 79611787
Device pacing issue 29.29 25.06 6 9848 130 79734404
Decreased appetite 28.95 25.06 4 9850 342414 79392120
Dyspnoea 28.17 25.06 39 9815 856986 78877548
Sinus bradycardia 28.11 25.06 24 9830 25223 79709311
Product use issue 26.55 25.06 71 9783 209751 79524783
Acute respiratory failure 25.44 25.06 34 9820 59507 79675027
Trigemino-cardiac reflex 25.21 25.06 6 9848 263 79734271

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CM18 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Other hypnotics and sedatives
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:35717 hypnotics
FDA PE N0000175975 General Anesthesia
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Conscious sedation indication 314271007
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Cardiac Decompensation contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Preanesthesia to general anesthesia Indication
Cats Sedation and analgesia Indication
Dogs Preanesthesia to general anesthesia Indication
Dogs Sedation and analgesia Indication
Dogs Noise aversion Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Dexdomitor Orion Corp. 1
SILEO Orion Corp. 1
Dexmedesed Dechra Veterinary Products LLC 1
Dexmedetomidine Hydrochloride Injection Akorn Animal Health Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.36 acidic
pKa2 6.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 March 13, 2013 RX INJECTABLE INJECTION 8455527 Jan. 4, 2032 USE FOR SEDATION
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 March 13, 2013 RX INJECTABLE INJECTION 8455527 Jan. 4, 2032 USE FOR SEDATION
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 Nov. 14, 2014 RX INJECTABLE INJECTION 8455527 Jan. 4, 2032 USE FOR SEDATION
EQ 0.12MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL 10792246 June 26, 2039 ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
EQ 0.12MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL 11497711 June 26, 2039 ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
EQ 0.12MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL 11517524 June 26, 2039 ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
EQ 0.18MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL 10792246 June 26, 2039 ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
EQ 0.18MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL 11497711 June 26, 2039 ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
EQ 0.18MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL 11517524 June 26, 2039 ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.12MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL April 5, 2025 NEW PRODUCT
EQ 0.18MG BASE IGALMI BIOXCEL N215390 April 5, 2022 RX FILM BUCCAL, SUBLINGUAL April 5, 2025 NEW PRODUCT
EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 Jan. 31, 2020 RX INJECTABLE INJECTION Dec. 16, 2025 NEW PATIENT POPULATION
EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) PRECEDEX HOSPIRA N021038 Dec. 17, 1999 RX INJECTABLE INJECTION Dec. 16, 2025 NEW PATIENT POPULATION
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 March 13, 2013 RX INJECTABLE INJECTION Dec. 16, 2025 NEW PATIENT POPULATION
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 March 13, 2013 RX INJECTABLE INJECTION Dec. 16, 2025 NEW PATIENT POPULATION
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 Nov. 14, 2014 RX INJECTABLE INJECTION Dec. 16, 2025 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR AGONIST Ki 9.70 IUPHAR CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST Ki 9.30 IUPHAR CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST EC50 8.82 CHEMBL CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.50 PDSP
Alpha-1A adrenergic receptor GPCR Ki 6.70 PDSP
Alpha-1D adrenergic receptor GPCR Ki 10.82 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 10.82 CHEMBL
Alpha-1A adrenergic receptor GPCR EC50 6.42 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 10.82 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 8.30 CHEMBL
Alpha-1B adrenergic receptor GPCR EC50 6.44 CHEMBL

External reference:

IDSource
4021214 VUID
N0000148660 NUI
D00514 KEGG_DRUG
145108-58-3 SECONDARY_CAS_RN
228054 RXNORM
4021214 VANDF
4021215 VANDF
C0113293 UMLSCUI
CHEBI:4466 CHEBI
CZX PDB_CHEM_ID
CHEMBL778 ChEMBL_ID
DB00633 DRUGBANK_ID
CHEMBL2106195 ChEMBL_ID
D020927 MESH_DESCRIPTOR_UI
5311068 PUBCHEM_CID
6277 INN_ID
521 IUPHAR_LIGAND_ID
67VB76HONO UNII
227894 MMSL
29394 MMSL
31641 MMSL
8598 MMSL
d04505 MMSL
008084 NDDF
008085 NDDF
116348007 SNOMEDCT_US
437750002 SNOMEDCT_US
438079000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9525 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 31 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9525 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 31 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9526 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 31 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9526 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 31 sections
Dexmedetomidine HCl HUMAN PRESCRIPTION DRUG LABEL 1 0143-9532 INJECTION 100 ug INTRAVENOUS ANDA 30 sections
Dexmedetomidine HCl HUMAN PRESCRIPTION DRUG LABEL 1 0143-9532 INJECTION 100 ug INTRAVENOUS ANDA 30 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9555 INJECTION 200 ug INTRAVENOUS ANDA 32 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9555 INJECTION 200 ug INTRAVENOUS ANDA 32 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9555 INJECTION 200 ug INTRAVENOUS ANDA 32 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9557 INJECTION 400 ug INTRAVENOUS ANDA 32 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9557 INJECTION 400 ug INTRAVENOUS ANDA 32 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9557 INJECTION 400 ug INTRAVENOUS ANDA 32 sections
PRECEDEX HUMAN PRESCRIPTION DRUG LABEL 1 0404-9938 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 18 sections
PRECEDEX HUMAN PRESCRIPTION DRUG LABEL 1 0404-9938 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 18 sections
PRECEDEX HUMAN PRESCRIPTION DRUG LABEL 1 0404-9938 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 18 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-0155 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 31 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1174 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 37 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1174 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 37 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1174 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 37 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1434 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1434 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1434 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1434 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1454 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 37 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1454 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 37 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1454 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 37 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1638 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1638 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1638 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 36 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1638 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 36 sections